Amgen, Servier sign licensing deal for cardiovascular drug

07/10/2013 | American City Business Journals · Drug Store News

Servier granted Amgen rights to market its heart failure and angina drug Procoralan, or ivabradine, in the U.S. as well as an exclusive option to develop and market its experimental heart failure drug S38844. Servier could get $50 million upfront plus milestone fees and sales royalties for ivabradine, which is already cleared in Europe. The deal also gives Servier rights to commercialize Amgen's heart failure drug candidate omecamtiv mecarbil in Europe.

View Full Article in:

American City Business Journals · Drug Store News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Fort Worth, TX